TARA vs. ACHL, INKT, SRZN, PLUR, NKGN, ESLA, SABS, CRTX, QNCX, and BCLI
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Achilles Therapeutics (ACHL), MiNK Therapeutics (INKT), Surrozen (SRZN), Pluri (PLUR), NKGen Biotech (NKGN), Estrella Immunopharma (ESLA), SAB Biotherapeutics (SABS), Cortexyme (CRTX), Quince Therapeutics (QNCX), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "medical" sector.
Protara Therapeutics (NASDAQ:TARA) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
Protara Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Protara Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 18.4% of Protara Therapeutics shares are held by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Protara Therapeutics had 1 more articles in the media than Achilles Therapeutics. MarketBeat recorded 7 mentions for Protara Therapeutics and 6 mentions for Achilles Therapeutics. Achilles Therapeutics' average media sentiment score of 1.11 beat Protara Therapeutics' score of 0.26 indicating that Achilles Therapeutics is being referred to more favorably in the news media.
Protara Therapeutics received 14 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 63.27% of users gave Protara Therapeutics an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Protara Therapeutics currently has a consensus target price of $26.50, suggesting a potential upside of 746.65%. Achilles Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 326.89%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protara Therapeutics is more favorable than Achilles Therapeutics.
Achilles Therapeutics' return on equity of -42.55% beat Protara Therapeutics' return on equity.
Summary
Protara Therapeutics beats Achilles Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
